Meclizine

Generic Name
Meclizine
Brand Names
Antivert, Bonine, Diphen, Dramamine, Travel-ease
Drug Type
Small Molecule
Chemical Formula
C25H27ClN2
CAS Number
569-65-3
Unique Ingredient Identifier
3L5TQ84570
Background

Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in t...

Indication

Indicated for the symptomatic treatment of nausea, vomiting, and dizziness associated with motion sickness, and management of vertigo due to various causes, including radiation sickness, Meniere’s syndrome, labyrinthitis and other vestibular disturbances.

Associated Conditions
Motion Sickness, Vertigo
Associated Therapies
-
Clinical Trials
Related News

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Not Applicable
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Procedure: Automated recommendation at the start of the case
Procedure: Automated notification at the start of surgery
Procedure: Automated notification at the end of surgery
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Procedure: Elective surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Isoflurane
Drug: Desflurane
Drug: Scopolamine
Drug: Droperidol
Drug: Haloperidol
Drug: Dexamethasone
Drug: Promethazine
Drug: Meclizine
Drug: Aprepitant
Drug: Metoclopramide
Drug: Fentanyl
Drug: Sufentanil
Drug: Alfentanil
Drug: Remifentanil
Drug: Morphine
Drug: Meperidine
Drug: Hydromorphone
Drug: Methadone
Drug: Oxycodone
Drug: Oxymorphone
Drug: Hydrocodone
Drug: Ketamine
Drug: Ondansetron
Drug: Granisetron
Drug: Dolasetron mesylate
Drug: Palonosetron
Drug: Tropisetron
Drug: Ramosetron
First Posted Date
2015-12-09
Last Posted Date
2019-03-07
Lead Sponsor
Vanderbilt University
Target Recruit Count
27034
Registration Number
NCT02625181
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Phase 3
Completed
Conditions
Vertigo, Peripheral
Interventions
Drug: Meclizine
Drug: Dimenhydrinate
First Posted Date
2014-04-14
Last Posted Date
2023-02-08
Lead Sponsor
Apsen Farmaceutica S.A.
Target Recruit Count
292
Registration Number
NCT02112578
Locations
🇧🇷

Clinica de Alergia MarttiAntila, Sorocaba, São Paulo, Brazil

🇧🇷

ISPEM, São José dos Campos, São Paulo, Brazil

🇧🇷

Clinilive, Maringá, Paraná, Brazil

and more 4 locations

The Effects of Antihistamines on Pre-Pulse Inhibition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Meclizine
First Posted Date
2012-02-23
Last Posted Date
2013-01-16
Lead Sponsor
Duke University
Target Recruit Count
117
Registration Number
NCT01537471
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Meclizine as a Potential Smoking Cessation Treatment

First Posted Date
2011-09-30
Last Posted Date
2014-08-01
Lead Sponsor
Duke University
Target Recruit Count
146
Registration Number
NCT01443858
Locations
🇺🇸

Duke Center for Nicotine and Smoking Cessation Research, Winston-Salem, North Carolina, United States

Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

First Posted Date
2008-03-24
Last Posted Date
2018-04-03
Lead Sponsor
Lehigh Valley Hospital
Target Recruit Count
26
Registration Number
NCT00641797
Locations
🇺🇸

Lehigh Valley Hospital, Allentown, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy